Today: 7 February 2026
Subscribe
Browse Category

KRX:005490 News 9 December 2025 - 23 January 2026

POSCO Holdings Inc Stock (005490, PKX): LFP Cathode JV, US Expansion, and Fresh 2026 Analyst Forecasts on Dec. 24, 2025

POSCO Holdings Inc Stock (005490, PKX): LFP Cathode JV, US Expansion, and Fresh 2026 Analyst Forecasts on Dec. 24, 2025

December 24, 2025 — POSCO Holdings Inc. is ending the year with a familiar identity crisis—in a good way for investors. It’s still a steel heavyweight, but more and more of the market narrative is about battery materials, lithium resource security, and “green steel” pathways that could reshape earnings power over the next few years. On Dec. 24, 2025, POSCO Holdings’ Korea-listed shares closed at KRW 314,000 (+3.29%) as attention returned to the group’s “second engine”: energy and battery materials. Investing.com What changed today isn’t a single line item in a quarterly report. It’s momentum—driven by a concrete project announcement
24 December 2025
·
Mineral Resources (ASX:MIN) Stock Update: POSCO Lithium Deal, Onslow Iron Ramp-Up, Debt Path and Latest Forecasts (21 December 2025)

Mineral Resources (ASX:MIN) Stock Update: POSCO Lithium Deal, Onslow Iron Ramp-Up, Debt Path and Latest Forecasts (21 December 2025)

Mineral Resources Limited (ASX: MIN) — “MinRes” — is back in the spotlight as investors weigh a very 2025 kind of trade-off: strong operational momentum (Onslow Iron hitting scale, new Pilbara projects starting) versus balance-sheet gravity and governance headlines. As of 21 December 2025, MinRes shares are trading around A$52.65, near the top of their 52‑week range (A$14.05 to A$53.38), with a listed market cap around A$10.36 billion. Investing.com Below is a detailed roundup of the latest news, the key catalysts, and the most widely referenced forecasts and analyst-style valuations shaping MinRes sentiment right now. Mineral Resources share price snapshot
21 December 2025
····
PLS Group Limited (ASX:PLS) Share Price, UBS Upgrade and 2026 Forecast: What the Rebranded Pilbara Minerals Means for Investors

PLS Group Limited (ASX:PLS) Share Price, UBS Upgrade and 2026 Forecast: What the Rebranded Pilbara Minerals Means for Investors

As of the afternoon of 9 December 2025, PLS Group Limited (still widely known by its former name Pilbara Minerals) is trading around A$4.11 on the ASX, up a little over 2% for the session and sitting just a few percent below its 52‑week high of A$4.26. The stock has climbed roughly 80% over the last 12 months, giving the lithium producer a market capitalisation close to A$13 billion.StockAnalysis The latest leg of the rally follows a broker U‑turn from UBS on the lithium sector, a strong technical uptrend signal, and the company’s recent rebrand from Pilbara Minerals Limited to
9 December 2025
·····

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop